| Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics RV Rawson, ER Shteinman, S Ansar, IA Vergara, JF Thompson, GV Long, ... Pathology 54 (7), 863-873, 2022 | 9 | 2022 |
| Causes, consequences and clinical significance of aneuploidy across melanoma subtypes ER Shteinman, JS Wilmott, IP da Silva, GV Long, RA Scolyer, IA Vergara Frontiers in Oncology 12, 988691, 2022 | 2 | 2022 |
| Novel approaches to measuring tumor-mutational burden provide insights into tumor-immune interaction in primary melanoma ER Shteinman, N Maher, JW Conway, GH Attrill, F Newell, N Waddell, ... Cancer Research 84 (6_Supplement), 5563-5563, 2024 | | 2024 |
| Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma ER Shteinman, IA Vergara, RV Rawson, SN Lo, N Maeda, K Koyama, ... Pathology 55 (5), 629-636, 2023 | | 2023 |
| Spatial organization of the tumour immune microenvironment (TIME) in primary and metastatic melanoma is associated with patient outcome GH Attrill, ER Shteinman, X Bai, F Marsh-Wakefield, C Quek, U Palendira, ... Cancer Research 83 (7_Supplement), 2369-2369, 2023 | | 2023 |
| Implementation of the personalised immunotherapy platform in a pilot study to predict immunotherapy response in metastatic melanoma TN Gide, S Lo, C Quek, IA Vergara, IP da Silva, P Shang, E Shteinman, ... | | 2022 |
| Molecular and clinical correlates of HER3 expression in melanoma RA Scolyer, ER Shteinman, IA Vergara, RV Rawson, SN Lo, N Maeda, ... | | 2022 |
